Skip to main content
Premium Trial:

Request an Annual Quote

Microbead Developer CyVera Becomes Subsidiary of Illumina

NEW YORK, April 12 (GenomeWeb News) - Illumina has completed its previously announced acquisition of microbead developer CyVera for $17.5 million in stock and cash, the company said yesterday.

 

Illumina acquired the Connecticut-based company for 1.6 million of its shares of common stock and $2.5 million in cash, which includes CyVera's liabilities. Illumina also assumed CyVera's outstanding stock options.

 

Illumina first announced in February that it intended to purchase CyVera, which is now a wholly owned Illumina subsidiary.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.